{"id":"tp-40234","type":"article-newspaper","title":"Merck and Moderna Report 42% Relative Risk Reduction in Melanoma Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40234","datePublished":"2026-10-24T18:54:20.000Z","dateModified":"2026-10-24T18:54:20.000Z","language":"en","abstract":"The iShares Biotechnology ETF (IBB) had a year-to-date NAV total return of 25.41% as of Oct. 21.","section":"Business","references":[]}